XM does not provide services to residents of the United States of America.
G
G

Galapagos


News

Galapagos tops BEL20 on encouraging trial data for cancer treatment

BUZZ-Galapagos tops BEL20 on encouraging trial data for cancer treatment ** Shares in Galapagos GLPG.AS rise 4 % after the Belgian biotech company presented "encouraging" new data for its blood cancer treatment GLPG5101 on Friday ** Galapagos says "no unexpected safety findings were observed and treatment with GLPG5101 resulted in high complete res
G

Galapagos Presents Encouraging New Data For Cd19 Car-T Candidate Glpg5101 In Non-Hodgkin Lymphoma At Eha 2024

BRIEF-Galapagos Presents Encouraging New Data For Cd19 Car-T Candidate Glpg5101 In Non-Hodgkin Lymphoma At Eha 2024 Galapagos NV GLPG.AS : GALAPAGOS PRESENTS ENCOURAGING NEW DATA FOR CD19 CAR-T CANDIDATE GLPG5101 IN NON-HODGKIN LYMPHOMA AT EHA 2024 GALAPAGOS NV - GLPG5101 SHOWED AN ENCOURAGING SAFETY PROFILE WITH MOST TEAES OF GRADE 1 OR 2 IN ONGOI
G

Galapagos And Adaptimmune Sign Clinical Collaboration Agreement With An Option To Exclusively License Adaptimmune’s Uza-Cel In Head & Neck Cancer And Potential Future Solid Tumor Indications

BRIEF-Galapagos And Adaptimmune Sign Clinical Collaboration Agreement With An Option To Exclusively License Adaptimmune’s Uza-Cel In Head & Neck Cancer And Potential Future Solid Tumor Indications May 30 (Reuters) - Adaptimmune Therapeutics PLC ADAP.O : REG-GALAPAGOS AND ADAPTIMMUNE SIGN CLINICAL COLLABORATION AGREEMENT WITH AN OPTION TO EXCLUSIV
G

FLSmidth, Neste, Sonova Holding

EUROPE RESEARCH ROUNDUP- FLSmidth, Neste, Sonova Holding May 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including FLSmidth, Neste and Sonova Holding, on Monday. HIGHLIGHTS * FLSmidth FLS.CO : JP Morgan raises target price to DKK 400 from DKK 310 * IMCD NV IMCD.AS : JP Morgan cuts target price to EUR 185 from EUR 188 * Neste Oyj NESTE.HE : Stifel cuts target price to EUR 37 from EUR 40 * Sonova Holding AG SOON.S : Morgan Stanley cuts
B
C
C
E
E
E
F
F
G
N
P
R
S
S
S
S
T
U
U
V
A
F
R

Galapagos jumps on collaboration with Blood Centers of America

BUZZ-Galapagos jumps on collaboration with Blood Centers of America ** Shares in Galapagos GLPG.AS rise about 3%, after the Belgium-based drugmaker announced a collaboration with Blood Centers of America (BCA) ** This collaboration gives Galapagos access to BCA's network of over 50 sites in the U.S. for the decentralised manufacturing (POC) of its
G

Britvic, Energean, Pandora

EUROPE RESEARCH ROUNDUP- Britvic, Energean, Pandora May 16 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Britvic, Energean and Pandora, on Thursday. HIGHLIGHTS * Britvic Plc BVIC.L : Peel Hunt raises target price to 1100p from 1000p * Energean Plc ENOG.L : Jefferies raises target price to 1,350p from 1,250p * Pandora PNDORA.CO : Citigroup raises target price to DKK 1330 from DKK 1255 * Surgical Science Sweden AB SUSW.ST : Berenbe
A
B
B
B
C
C
C
C
E
E
E
E
F
G
G
H
H
H
I
I
N
T
T
U
V
A
E
P

Galapagos Says Total Operating Loss From Continuing Operations For Three Months Ended 31 March 2024 Was EUR 33.1 Million

BRIEF-Galapagos Says Total Operating Loss From Continuing Operations For Three Months Ended 31 March 2024 Was EUR 33.1 Million May 2 (Reuters) - Galapagos NV GLPG.AS : GALAPAGOS - TOTAL OPERATING LOSS FROM CONTINUING OPERATIONS FOR THREE MONTHS ENDED 31 MARCH 2024 WAS EUR 33.1 MILLION, COMPARED TO EUR 14.2 MILLION PLAN TO FILE INVESTIGATIONAL NEW DRUG APPLICATIONS IN U.S.
G

Galapagos NV <GLPG.OQ> expected to post a loss of 13 cents a share - Earnings Preview

Galapagos NV expected to post a loss of 13 cents a share - Earnings Preview Galapagos NV GLPG.OQ , GLPG.O is expected to show a fall in quarterly revenue when it reports results on May 2 for the period ending March 31 2024 The Malines (mechelen) Antwerpen-based company is expected to report a 63.2% decrease in revenue to €65.877 million from €178.87 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
G

Galapagos NV <GLPG.AS> expected to post a loss of 14 cents a share - Earnings Preview

Galapagos NV expected to post a loss of 14 cents a share - Earnings Preview Galapagos NV GLPG.AS is expected to report results on May 2 for the period ending March 31 2024 ​LSEG's mean analyst estimate for Galapagos NV is for a loss of 14 cents per share. The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 10 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three mon
G

Alfen, Boliden, Pennon Group

EUROPE RESEARCH ROUNDUP-Alfen, Boliden, Pennon Group April 17 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfen, Boliden and Pennon Group on Wednesday. HIGHLIGHTS * Alfen ALFEN.AS : Deutsche Bank cuts to hold from buy * Boliden AB BOL.ST : JP Morgan raises to neutral from underweight * Pennon Group Plc PNN.L : RBC raises to outperform rating * Picton Property Income Ltd PCTN.L : Peel Hunt raises to buy from hold * URW URW.PA :
A
A
A
B
B
B
B
B
B
C
C
E
E
E
F
G
H
H
L
N
P
A
A
B
B
B
D



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.